Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.
Gowri SatyanarayanaKyle T EnriquezTianyi SunElizabeth J KleinMaheen Z AbidiShailesh M AdvaniJoy AwosikaZiad BakounyBabar BashirStephanie BergMarilia BernardesPamela C EganArielle ElkriefLawrence E FeldmanChristopher R FrieseShipra GoelCyndi Gonzalez GomezKeith L GrantElizabeth A GriffithsShuchi GulatiShilpa GuptaClara HwangJayanshu JainChinmay JaniAnna KaltsasAnup KasiHina KhanNatalie KnoxVadim S KoshkinDaniel H KwonChris LabakiGary H LymanRana R McKayChristopher McNairGayathri NagarajElizabeth S NakasoneRyan NguyenTaylor K NonatoAdam J OlszewskiOrestis A PanagiotouMatthew PucPedram RazaviElizabeth V RobilottiMiriam Santos-DutraAndrew L SchmidtDimpy P ShahSumit A ShahKendra VieiraLisa B WeissmannTrisha M Wise-DraperUlysses WuJulie Tsu-Yu WuToni K ChoueiriSanjay MishraJeremy L WarnerBenjamin FrenchDimitrios FarmakiotisPublished in: Open forum infectious diseases (2022)
Viral and fungal coinfections are infrequent among patients with cancer and COVID-19, with the latter associated with very high mortality rates. Clinical and laboratory parameters can be used to guide early empiric antimicrobial therapy, which may improve clinical outcomes.